论文部分内容阅读
目的对紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌的临床疗效进行探讨。方法随机选取卵巢癌患者共96例作为实验对象,均为我院2014-05-2015-05收治将其按照不同治疗方法均分成人数相等的两组,就紫杉醇联合顺铂治疗(对照组,n=48)与紫杉醇联合顺铂静脉和腹腔双途径治疗(观察组,n=48)的临床疗效展开对比分析。结果从治疗效率方面分析,观察组患者的治疗总有效率为79.16%,对照组患者的治疗总有效率为62.50%,两组对比,观察组明显高于对照组,组间差异明显,经χ2检验,证明有统计学研究意义,P<0.05,从不良反应发生情况方面分析,观察组患者的不良反应发生率为14.58%,对照组患者的不良反应发生率为27.08%,两组对比,观察组显著低于对照组,组间差异明显,经χ2检验,证明P<0.05,有统计学研究意义。结论紫杉醇联合顺铂静脉和腹腔双途径治疗晚期卵巢癌的应用效果较好,安全可靠且不良反应发生率少,对改善患者的生存质量也有积极的影响。
Objective To investigate the clinical efficacy of paclitaxel plus cisplatin in the treatment of advanced ovarian cancer by both intraperitoneal and intravenous routes. Methods A total of 96 patients with ovarian cancer were randomly selected as the experimental subjects, all of our hospital 2014-05-2015-05 admitted to their treatment according to different methods were equally divided into two groups, paclitaxel combined with cisplatin treatment (control group, n = 48) and paclitaxel plus cisplatin intravenous and intraperitoneal double-channel treatment (observation group, n = 48) were analyzed. Results From the analysis of therapeutic efficiency, the total effective rate of observation group was 79.16%, while the total effective rate of control group was 62.50%. Compared with the control group, the observation group was significantly higher than the control group, the difference was significant Test, proves statistically significant (P <0.05). According to the analysis of adverse reactions, the incidence of adverse reactions in the observation group was 14.58%, and that in the control group was 27.08%. The comparison and observation of the two groups Group was significantly lower than the control group, significant differences between groups, by χ2 test, P <0.05, statistically significant. Conclusion The combination of paclitaxel and cisplatin intravenous and intraperitoneal routes in the treatment of advanced ovarian cancer is effective, safe and reliable, and the incidence of adverse reactions is small, which has a positive impact on improving the quality of life of patients.